Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
8 Apr 24
8-K
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25 Mar 24
8-K
Termination of a Material Definitive Agreement
1 Mar 24
8-K
Entry into a Material Definitive Agreement
26 Feb 24
8-K
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8 Jan 24
8-K
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
11 Dec 23
8-K
Departure of Directors or Certain Officers
20 Nov 23
8-K
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
11 Sep 23
8-K
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
7 Aug 23
8-K
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
10 Jul 23
8-K
Departure of Directors or Certain Officers
3 Jul 23
8-K
Completion of Acquisition or Disposition of Assets
30 Jun 23
8-K
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
26 Jun 23
8-K
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
12 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
31 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
8 May 23
8-K
MaRKER Announces LeADERSHIP TRANSITION & ProVIdes UPDATE ON OPERATIONAL STRATEGY
1 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
424B5
Prospectus supplement for primary offering
22 Mar 23
8-K
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
22 Mar 23
10-K
2022 FY
Annual report
22 Mar 23
8-K
Departure of Directors or Certain Officers
16 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
26 Jan 23
424B3
Prospectus supplement
3 Jan 23
EFFECT
Notice of effectiveness
3 Jan 23
CORRESP
Correspondence with SEC
29 Dec 22
UPLOAD
Letter from SEC
29 Dec 22
S-1
IPO registration
23 Dec 22
8-K
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
13 Dec 22
8-K
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
22 Nov 22
8-K
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
10 Nov 22
Latest ownership filings
3
Eliot M Lurier
5 Jul 23
4
Norman David Eansor
8 Jun 23
4
Katharine Knobil
8 Jun 23
4
John Robert Wilson
8 Jun 23
4
STEVE ELMS
8 Jun 23
4
Juan Vera
11 May 23
SC 13D/A
Aisling Capital IV, LP
3 Mar 23
4
Tsvetelina P Hoang
1 Mar 23
4
Mythili Koneru
1 Mar 23
4
Michael Loiacono
1 Mar 23
4
Juan Vera
1 Mar 23
4
Anna Szymanska
1 Mar 23
4
Nadia Agopyan
1 Mar 23
4
John Robert Wilson
26 May 22
4
David Laskow-Pooley
26 May 22
4
Katharine Knobil
26 May 22
4
Norman David Eansor
26 May 22
4
STEVE ELMS
26 May 22
4
Peter L. Hoang
28 Mar 22
4
Juan Vera
28 Mar 22
4
Anthony H. Kim
28 Mar 22
4
Peter L. Hoang
22 Feb 22
4
Juan Vera
22 Feb 22
4
Anna Szymanska
22 Feb 22
4
Michael Loiacono
22 Feb 22
4
Mythili Koneru
22 Feb 22
4
Anthony H. Kim
22 Feb 22
4
Tsvetelina P Hoang
22 Feb 22
4
Gerald Garrett
22 Feb 22
4
Nadia Agopyan
22 Feb 22
4
Katharine Knobil
9 Dec 21
3
Katharine Knobil
9 Dec 21
4
Frederick Gerald Wasserman
10 Jun 21
4
David Laskow-Pooley
10 Jun 21
4
STEVE ELMS
10 Jun 21
4
Norman David Eansor
10 Jun 21
4
John Robert Wilson
10 Jun 21
4
Frederick Gerald Wasserman
20 May 21
SC 13D/A
New Enterprise Associates 16, L.P.
26 Mar 21
SC 13D/A
Leen Ann M.
24 Mar 21